Article

Diabetic foot ulcers (DFUs) are a common and serious complication of diabetes, leading to disabilities, reduced quality of life, and high costs. The pathophysiology of DFUs involves metabolic dysfunction, diabetic immunopathy, diabetic neuropathy, and angiopathy, which can lead to infections and other complications. Understanding and addressing these factors can help prevent and manage DFUs more effectively.

Diabetes Mellitus (DM) is a metabolic disorder that can lead to various complications, including anemia. Chronic hyperglycemia causes changes in red blood cells (RBCs) that make them more susceptible to being cleared from circulation. This review discusses the mechanisms behind these changes and their impact on microangiopathy in DM.

This research paper discusses the growing prevalence of immune-related diabetes mellitus (irDM) caused by immune checkpoint inhibitors (ICPis). It proposes a two-pronged approach to advance knowledge and understanding of irDM, focusing on both the scientific and patient-centered aspects. The paper suggests a multidisciplinary effort to improve characterization, standardization, and treatment of irDM.

This study examined 16 years of hyperglycaemia-related testing in Australia and found that the proportion of encounters for prediabetes and type 2 diabetes management has increased over time. GPs were influenced by changes in national insurance and clinical guidelines, but there was also evidence of “unendorsed” testing. This has significant resource implications and calls for an economic analysis to lower the risk threshold for prediabetes screening. Ongoing data is needed to inform clinical practice and policy in Australia.

Type 2 diabetes, which constitutes nearly 90% of the 537 million diabetes cases globally, is rapidly increasing, particularly among children and young adults. The research emphasizes the importance of early detection and management to prevent complications, highlights the potential of precision medicine and novel therapies, and discusses the barriers to effectively addressing the diabetes epidemic.

Subcutaneous semaglutide is effective for weight loss in individuals with obesity without diabetes, achieving an average reduction of 11.85% from baseline compared to placebo. However, the treatment is associated with a higher risk of gastrointestinal adverse events, treatment discontinuation, and serious adverse event

The prevalence of cardiometabolic multimorbidity (co-existence of ≥1 cardiometabolic diseases) in the U.S. has been increasing significantly from 1999 to 2018, with a prevalence of 14.4% in 2017-2018. This trend was observed in both genders, most age groups, and non-Hispanic White people. The most common patterns were hypertension and diabetes, hypertension, diabetes, and CHD, and hypertension and CHD. This highlights the growing concern of cardiometabolic multimorbidity as a public health issue in the U.S.